

## Curriculum Vitae

<b>Surname:</b>	BATH
<b>Forename:</b>	Philip Michael William
<b>Current Position and organisation:</b>	Stroke Association Professor of Stroke Medicine and Head, Academic Stroke & Stroke Trials Unit, University of Nottingham Honorary Consultant Stroke Physician, Nottingham University Hospitals NHS Trust
<b>Address:</b>	Queen's Medical Centre, Nottingham NG7 2UH
<b>Tel:</b>	0115 823 1765 (mobile 07798 670726)
<b>Email:</b>	philip.bath@nottingham.ac.uk

<b>Qualifications/Fellowships:</b>			
B.Sc.	University of London	1979	Physiology
M.B., B.S.	University of London	1982	
M.R.C.P. (UK)	Royal College Physicians (UK)	1986	
M.D.	University of London	1991	Rogers Prize
F.R.C.P.	Royal College Physicians (London)	1998	
Dip. Clin. Hypertension	European Society Hypertension	2002	
F.R.C.Path	Royal College Pathologists	2005	Published research
F.E.S.O.	European Stroke Organization	2005	
F.A.H.A.	American Heart Association	2014	
D.Sc.	University of Nottingham	2015	
F.Med.Sci.	Academy Medical Sciences	2016	
F.W.S.O.	World Stroke Organization	2018	President's Award 2021
<b>Posts Held:</b>			
Mar 98 continuing			
Professor	University of Nottingham, Nottingham NG7 2UH		Stroke Medicine
Hon. Consultant	Queen's Medical Centre, Nottingham NG7 2UH		Stroke
<b>Current/recent research funding:</b>			
1. Van der Worp B, <b>Bath P</b> , Berge E, Ciccone A, Csiba L, de Winter R, Dippel D, Kobayashi A, Korv J, Lees K, Macleod M, Thomalla G, van de Beek D, Borregaard S, Ntaios G, Randall G, Fuchs B. PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS). <b>EU Horizon 2020</b> , 634809. €5,994,000. 9/2015, 5 years. RH4810			
2. Hamdy S, Rothwell J, <b>Bath PM</b> . An exploration of the application of non-invasive cerebellar stimulation in the neurorehabilitation of dysphagia after stroke. <b>MRC</b> , MR/P006183/1. £845,572. 7/7/2017-6/10/2020. RA48DS			
3. Wardlaw J, <b>Bath P</b> , Doubal F, Dennis M, England T, Sprigg N, Cvorov V, Werring D, Hassan A, Montgomery A. LACunar Intervention (LACI) Trial: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease. <b>British Heart Foundation</b> , CS/15/5/31475. £747,598. 1/11/17-31/10/20. RB48XA			
4. Wardlaw JM, Markus HS, O'Brien JT, Doubal F, Quinn TJ, Touz RM, O'Sullivan M, Williams S, Robinson TG, Tyrell P, <b>Bath PM</b> , Sprigg N, McManus RJ, Werring DJ, Rudd A, Haig E. Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD). <b>Stroke Association</b> , £1,279,476.			
5. Majid A, Lawrence CB, Redgrave J, Ince PG, Kennerley AJ, Cousens L, Buchan AM, <b>Bath PM</b> . MICA: Efficacy and safety evaluation of AZD1236 (Matrix metalloproteinase 9 & 12 inhibitor) in experimental stroke. <b>MRC</b> , MR/R005923/1. £721K. 20/11/2017-18/5/2021.			
6. Sprigg N, <b>Bath PM</b> . Desmopressin for treatment of patients taking Antiplatelet agents with Stroke due to Haemorrhage. RfPB PB-PG-0816-20011. 1/6/18.			
7. England T, <b>Bath PM</b> , Dineen R, O'Sullivan S, Bell R, Sprigg N, Werring D, Dawson J, Hausenloy D, Montgomery A, Webb J, Gordon A, Yellon D. Remote Ischaemic Conditioning After Stroke 3 (RECAST-3): A multicentre randomised controlled trial. <b>NIHR EME</b> , NIHR128240. £1,658,613. 4/2020-12/2023			
8. <b>Bath PM</b> , Chen X, Garibaldi J, Montgomery A, Quinn T, Sprigg N, Woodhouse L. Assessment of modern machine learning methods and conventional statistical regression techniques in diagnosis and prediction of outcome after acute stroke using big data. <b>British Heart Foundation</b> , PG/19/69/34636. £145,079. 5/2020-2022.			
9. <b>Bath PM</b> , Gordon A, Jaki T, Ball J, Rick C, Montgomery A, Juszczak E, Logan P, Lim WS, Royal S, Gage H, Guthrie B, Lasserson D, Howard R, Glover M, Leighton P, Passmore P,			

Hewitt J, Shenkin S, Quinlan P, Godfrey M. Prophylaxis Treatment of COVID in care homes trial (PROTECT) - Set up and maintenance. NIHR XP, NIHR133443. £1,726,187. 1/1/21-31/12/22.

10. Sprigg N, **Bath PM**, Roberts I, Hepburn T, Montgomery A, Salman R A-S, Roffe C, Werring D, England T, Coats, T, James M, Rick C, Robinson TG, Dineen R, Desborough M, Gard T. Tranexamic acid for hyper acute spontaneous intracerebral haemorrhage TICH-3. **NIHR HTA**, NIHR129917, £4,464,044. 1/5/21-30/4/28.
11. **Bath PM**, Gordon A, Jaki T, Ball J, Rick C, Montgomery A, Juszczak E, Logan P, Lim WS, Royal S, Gage H, Guthrie B, Lasserson D, Howard R, Glover M, Leighton P, Passmore P, Hewitt J, Shenkin S, Quinlan P, Godfrey M. Prophylaxis Treatment of COVID in care homes trial (PROTECT) - Set up and maintenance. **NIHR XP**, NIHR133443. £1,726,187. 1/1/21-31/12/22.
12. Roffe C, **Bath P**, Warusevitane A, Smith C, Dixit A, Sprigg N, Helliwell B, Phillips N, Sim J, Jowett S, Ogollah R. The Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a single-blind, randomized controlled trial of metoclopramide for the prevention of pneumonia in patients with dysphagia after an acute stroke. **NIHR HTA**, NIHR130689. £2,201,286. 1/5/21-30/4/25.
13. **Bath PM**, Hamdy S, England T, Montgomery A, James M, Sprigg N, Smith C, Everton L, Shone A, Iversen H, Matz K, Dziewas R, Coult M. Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST). NIHR HTA, NIHR132016 £1,470,188. 1/1/21.

#### Key Publications:

1. **Bath PMW**, Lindenstrom E, Boysen G, et al, for the tardis Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. **Lancet** 2001;358:702-10. [Chief Investigator]
2. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): a randomised controlled trial. **Lancet** 2004;363:439-45. [MRC grant applicant, Trial Steering Committee member]
3. Sacco RL, Diener HC, Yusuf S, et al, **Bath P**, et al; the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent strokes. **NEJM** 2008;359(12):1238-51. Aug 27 (epub). [Member, Trial Steering Committee]
4. Yusuf S, Diener HC, Sacco RL, et al, **Bath P**, et al; the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. **NEJM** 2008;359(12):1225-37. Aug 27 (epub). [Member, Trial Steering Committee]
5. Diener H-C, Sacco RL, Yusuf S, et al, **Bath P**, et al, for the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole and telmisartan on disability of recurrent stroke and cognitive function in patients with ischemic stroke: Results from the randomised Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Trial. **Lancet Neurology** 2008;7(10):875-84. Aug 29 epub [Member, Trial Steering Committee]
6. Sandset EC, **Bath PM**, Boysen G, et al; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo controlled, double-blind trial. **Lancet** 2011;377:741-50. Epub 26 Feb 2011. [Member, Trial Steering Committee; Advisor, analysis of primary outcome]
7. Whiteley WN, Adams HP Jr, **Bath PM**, et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. **Lancet Neurology** 2013 Jun;12(6):539-45. doi: 10.1016/S1474-4422(13)70079-6.
8. **Bath PM**, Woodhouse L, Scutt P, et al; for ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. **Lancet**. 2015 Feb 14;385(9968):617-28. [Chief Investigator]
9. Kalladka D, Sinden J, Pollock K, et al, **Bath PM**, Dunn L, Muir KW. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. **Lancet** 2016 Aug 20;388(10046):787-96. doi: 10.1016/S0140-6736(16)30513-X. Epub 2016 Aug 3. PMID: 27497862 [Initially Chief Investigator, latterly Chair DMC]
10. **Bath PM**, Woodhouse LJ, Appleton JP, et al; TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. **Lancet** 2017 Dec 20. [Chief Investigator]

11. Sprigg N, Flaherty K, Appleton JP, et al, **Bath PM**; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. **Lancet** 2018 May 26;391(10135):2107-2115. [Deputy Chief Investigator]
12. Dziejewas R, Stellato R, van der Tweel I, et al, **Bath PM**, on behalf of the PHAST-TRAC Investigators. PHaryngeal electrical STimulation for early decannulation in TRACheotomised stroke patients with neurogenic dysphagia (PHAST-TRAC): a prospective randomised single-blinded trial. **Lancet Neurol** 2018; 17; 849-59. [Chair, Steering Committee]
13. **Bath PM**, Scutt P, Anderson CS, et al; for the RIGHT-2 Investigators. Pre-hospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): a randomised, sham-controlled, blinded, phase III, superiority ambulance-based trial. **Lancet** 2019 Feb 6. [Chief Investigator]
14. Anderson CS, Huang Y, Lindley RI, et al, **Bath PM**, et al; ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. **Lancet** 2019 Mar 2;393(10174):877-888.
15. van der Worp HB, Macleod MR, **Bath PM**, et al; EuroHYP-1 investigators. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. **Eur Stroke J**. 2019 Sep;4(3):254-262.
16. Muir KW, Bulters D, Willmot M, et al, **Bath P**, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). **J Neurol Neurosurg Psychiatry**. 2020 Apr;91(4):396-401.
17. **Bath PM**, Woodhouse LJ, Suntrup-Krueger S, et al; for PHADER Investigators. Pharyngeal electrical stimulation for neurogenic dysphagia following stroke, traumatic brain injury or other causes: Main results from the PHADER cohort study. **EClinicalMedicine**. 2020 Nov 10;28:100608. [Chief Investigator]
18. Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, **Bath PM**, et al; CHANCE-2 Investigators. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. **N Engl J Med**. 2021 Dec 30;385:2520-2530.
19. Hubert GJ, Hubert ND, Maegerlein C, et al, **Bath PM**, Audebert HJ, Haberl RL. Association Between Use of a Flying Intervention Team vs Patient Interhospital Transfer and Time to Endovascular Thrombectomy Among Patients With Acute Ischemic Stroke in Nonurban Germany. **JAMA**. 2022 May 5. doi: 10.1001/jama.2022.5948. [Methodology advisor]
20. Pan Y, Meng X, Jin A, Johnston SC, Li H, **Bath PM**, et al. Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. **JAMA Neurol**. 2022 Aug 1;79(8):739-745.



4 January 2023